Citations

Clear

1053 citation(s) found for "Andre, F".

High‐Resolution Molecular Validation of Self‐Renewal and Spontaneous Differentiation in Clinical‐Grade Adipose‐Tissue Derived Human Mesenchymal Stem Cells
Dudakovic, Amel , Camilleri, Emily T. , Riester, Scott M. , Lewallen, Eric A. , Kvasha, Sergiy M., Chen, Xiaoyue , Radel, Darcie J., Anderson, Jarett M., Nair, Asha, Evans, Jared M., Krych, Aaron J. , Smith, Jay , Deyle, David R. , Stein, Janet L. , Im, Hee‐Jeong , Cool, Simon M. , Dietz, Allan B. , Wijnen, André J. van , Camilleri, Emily , Stein, Gary S. , Westendorf, Jennifer J. , Kakar, Sanjeev , van Wijnen, Andre J , Krych, Aaron J , Dietz, Allan B , Camilleri, Emily

Mayo Clinic

Journal of Cellular Biochemistry | June 6, 2014 | Volume: 115 | Issue: 10 | Pages: 1816-1828

10.1002/jcb.24852 | PMID 24905804 Get It

AbstractImproving the effectiveness of adipose‐tissue derived human mesenchymal stromal/stem cells (AMSCs) for skeletal therapies requires a detailed characterization of mechanisms supporting cell proliferation and multi‐potency. We investigated the molecular phenotype of AMSCs that were either actively proliferating in platelet lysate or in a basal non‐proliferative state. Flow cytometry combined with high‐throughput RNA sequencing (RNASeq) and RT‐qPCR analyses validate that AMSCs express classic mesenchymal cell surface markers (e.g., CD44, CD73/NT5E, CD90/THY1, and CD105/ENG). Expression of CD90 is selectively elevated at confluence. Self‐renewing AMSCs express a standard cell cycle program that successively mediates DNA replication, chromatin packaging, cyto‐architectural enlargement, and mitotic division. Confluent AMSCs preferentially express genes involved in extracellular matrix (ECM) formation and cellular communication. For example, cell cycle‐related biomarkers (e.g., cyclins E2 and B2, transcription factor E2F1) and histone‐related genes (e.g., H4, HINFP, NPAT) are elevated in proliferating AMSCs, while ECM genes are strongly upregulated (>10‐fold) in quiescent AMSCs. AMSCs also express pluripotency genes (e.g., POU5F1, NANOG, KLF4) and early mesenchymal markers (e.g., NES, ACTA2) consistent with their multipotent phenotype. Strikingly, AMSCs modulate expression of WNT signaling components and switch production of WNT ligands (from WNT5A/WNT5B/WNT7B to WNT2/WNT2B), while upregulating WNT‐related genes (WISP2, SFRP2, and SFRP4). Furthermore, post‐proliferative AMSCs spontaneously express fibroblastic, osteogenic, chondrogenic, and adipogenic biomarkers when maintained in confluent cultures. Our findings validate the biological properties of self‐renewing and multi‐potent AMSCs by providing high‐resolution quality control data that support their clinical versatility. J. Cell. Biochem. 115: 1816–1828, 2014. © 2014 Wiley Periodicals, Inc.
microRNA‐Mediated Survivin Control of Pluripotency
Kapinas, Kristina, Kim, Heesun , Mandeville, Matthew, Martin‐Buley, Lori A., Lian, Jane B. , Wijnen, André J. van , Stein, Janet L. , Croce, Carlo Maria , Altieri, Dario C. , Stein, Gary S. , van Wijnen, Andre J

Mayo Clinic

Journal of Cellular Physiology | June 2, 2014 | Volume: 230 | Issue: 1 | Pages: 63-70

10.1002/jcp.24681 | PMID 24891298 Get It

Understanding the mechanisms that sustain pluripotency in human embryonic stem cells (hESCs) is an active area of research that may prove useful in regenerative medicine and will provide fundamental information relevant to development and cancer. hESCs and cancer cells share the unique ability to proliferate indefinitely and rapidly. Because the protein survivin is uniquely overexpressed in virtually all human cancers and in hESCs, we sought to investigate its role in supporting the distinctive capabilities of these cell types. Results presented here suggest that survivin contributes to the maintenance of pluripotency and that post‐transcriptional control of survivin isoform expression is selectively regulated by microRNAs. miR‐203 has been extensively studied in human tumors, but has not been characterized in hESCs. We show that miR‐203 expression and activity is consistent with the expression and subcellular localization of survivin isoforms that in turn modulate expression of the Oct4 and Nanog transcription factors to sustain pluripotency. This study contributes to understanding of the complex regulatory mechanisms that govern whether hESCs proliferate or commit to lineages. J. Cell. Physiol. 230: 63–70, 2015. © 2014 Wiley Periodicals, Inc.
Galectin-1 Drives Pancreatic Carcinogenesis through Stroma Remodeling and Hedgehog Signaling Activation
Martínez‐Bosch, Neus , Fernández‐Barrena, Maite G. , Moreno, Mireia , Ortíz-Zapater, Elena , Munné‐Collado, Jessica, Iglesias, Mar , André, Sabine , Gabius, Hans‐Joachim , Hwang, Rosa F. , Poirier, Françoise, Navas, Carolina, Guerra, Carmen , Fernández-Zapico, Martín E. , Navarro, Pilar , Navarro, Pilar

Mayo Clinic

Cancer Research | May 9, 2014 | Volume: 74 | Issue: 13 | Pages: 3512-3524

10.1158/0008-5472.can-13-3013 | PMID 24812270 Get It

Abstract Despite some advances, pancreatic ductal adenocarcinoma (PDAC) remains generally refractory to current treatments. Desmoplastic stroma, a consistent hallmark of PDAC, has emerged as a major source of therapeutic resistance and thus potentially promising targets for improved treatment. The glycan-binding protein galectin-1 (Gal1) is highly expressed in PDAC stroma, but its roles there have not been studied. Here we report functions and molecular pathways of Gal1 that mediate its oncogenic properties in this setting. Genetic ablation of Gal1 in a mouse model of PDAC (EIa-myc mice) dampened tumor progression by inhibiting proliferation, angiogenesis, desmoplasic reaction and by stimulating a tumor-associated immune response, yielding a 20% increase in relative lifesplan. Cellular analyses in vitro and in vivo suggested these effects were mediated through the tumor microenvironment. Importantly, acinar-to-ductal metaplasia, a crucial step for initiation of PDAC, was found to be regulated by Gal1. Mechanistic investigations revealed that Gal1 promoted Hedgehog pathway signaling in PDAC cells and stromal fibroblasts as well as in Ela-myc tumors. Taken together, our findings establish a function for Gal1 in tumor-stroma crosstalk in PDAC and provide a preclinical rationale for Gal1 targeting as a microenvironment-based therapeutic strategy. Cancer Res; 74(13); 3512–24. ©2014 AACR.
RUNX3 Facilitates Growth of Ewing Sarcoma Cells
Bledsoe, Krista L., McGee‐Lawrence, Meghan E. , Camilleri, Emily T. , Riester, Scott M. , Wijnen, André J. van , Oliveira, André M. , Camilleri, Emily , Wang, Xiaoke , Westendorf, Jennifer J. , van Wijnen, Andre J , McGee-Lawrence, Meghan E , Camilleri, Emily

Mayo Clinic

Journal of Cellular Physiology | May 8, 2014 | Volume: 229 | Issue: 12 | Pages: 2049-2056

10.1002/jcp.24663 | PMID 24812032 Get It

Ewing sarcoma is an aggressive pediatric small round cell tumor that predominantly occurs in bone. Approximately 85% of Ewing sarcomas harbor the EWS/FLI fusion protein, which arises from a chromosomal translocation, t(11:22)(q24:q12). EWS/FLI interacts with numerous lineage‐essential transcription factors to maintain mesenchymal progenitors in an undifferentiated state. We previously showed that EWS/FLI binds the osteogenic transcription factor RUNX2 and prevents osteoblast differentiation. In this study, we investigated the role of another Runt‐domain protein, RUNX3, in Ewing sarcoma. RUNX3 participates in mesenchymal‐derived bone formation and is a context dependent tumor suppressor and oncogene. RUNX3 was detected in all Ewing sarcoma cells examined, whereas RUNX2 was detected in only 73% of specimens. Like RUNX2, RUNX3 binds to EWS/FLI via its Runt domain. EWS/FLI prevented RUNX3 from activating the transcription of a RUNX‐responsive reporter, p6OSE2. Stable suppression of RUNX3 expression in the Ewing sarcoma cell line A673 delayed colony growth in anchorage independent soft agar assays and reversed expression of EWS/FLI‐responsive genes. These results demonstrate an important role for RUNX3 in Ewing sarcoma. J. Cell. Physiol. 229: 2049–2056, 2014. © 2014 Wiley Periodicals, Inc.
Transcriptional atlas of cardiogenesis maps congenital heart disease interactome
Martinez‐Fernandez, Almudena , Hartjes, Katherine A., Kocher, Jean‐Pierre , Olson, Timothy M. , Nelson, Timothy J., Martinez-Fernandez, Almudena, Xing, Li , Terzic, André , Nelson, Timothy J. , Olson, Timothy M

Mayo Clinic

Physiological Genomics | May 7, 2014 | Volume: 46 | Issue: 13 | Pages: 482-495

10.1152/physiolgenomics.00015.2014 | PMID 24803680 Get It

Mammalian heart development is built on highly conserved molecular mechanisms with polygenetic perturbations resulting in a spectrum of congenital heart diseases (CHD). However, knowledge of cardiogenic ontogeny that regulates proper cardiogenesis remains largely based on candidate-gene approaches. Mapping the dynamic transcriptional landscape of cardiogenesis from a genomic perspective is essential to integrate the knowledge of heart development into translational applications that accelerate disease discovery efforts toward mechanistic-based treatment strategies. Herein, we designed a time-course transcriptome analysis to investigate the genome-wide dynamic expression landscape of innate murine cardiogenesis ranging from embryonic stem cells to adult cardiac structures. This comprehensive analysis generated temporal and spatial expression profiles, revealed stage-specific gene functions, and mapped the dynamic transcriptome of cardiogenesis to curated pathways. Reconciling known genetic underpinnings of CHD, we deconstructed a disease-centric dynamic interactome encoded within this cardiogenic atlas to identify stage-specific developmental disturbances clustered on regulation of epithelial-to-mesenchymal transition (EMT), BMP signaling, NF-AT signaling, TGFb-dependent EMT, and Notch signaling. Collectively, this cardiogenic transcriptional landscape defines the time-dependent expression of cardiac ontogeny and prioritizes regulatory networks at the interface between health and disease.
Selection Via Pluripotency-Related Transcriptional Screen Minimizes the Influence of Somatic Origin on iPSC Differentiation Propensity
Hartjes, Katherine A., Martinez‐Fernandez, Almudena , Roemmich, Alexa Joanna, Larsen, Brandon T. , Li, Xing , Terzic, André , Nelson, Timothy J.

Mayo Clinic

Stem Cells | May 6, 2014 | Volume: 32 | Issue: 9 | Pages: 2350-2359

10.1002/stem.1734 | PMID 24802033 Get It

Abstract The value of induced pluripotent stem cells (iPSCs) within regenerative medicine is contingent on predictable and consistent iPSC differentiation. However, residual influence of the somatic origin or reprogramming technique may variegate differentiation propensity and confound comparative genotype/phenotype analyses. The objective of this study was to define quality control measures to select iPSC clones that minimize the influence of somatic origin on differentiation propensity independent of the reprogramming strategy. More than 60 murine iPSC lines were derived from different fibroblast origins (embryonic, cardiac, and tail tip) via lentiviral integration and doxycycline-induced transgene expression. Despite apparent equivalency according to established iPSC histologic and cytomorphologic criteria, clustering of clonal variability in pluripotency-related gene expression identified transcriptional outliers that highlighted cell lines with unpredictable cardiogenic propensity. Following selection according to a standardized gene expression profile calibrated by embryonic stem cells, the influence of somatic origin on iPSC methylation and transcriptional patterns was negated. Furthermore, doxycycline-induced iPSCs consistently demonstrated earlier differentiation than lentiviral-reprogrammed lines using contractile cardiac tissue as a measure of functional differentiation. Moreover, delayed cardiac differentiation was predominately associated with upregulation in pluripotency-related gene expression upon differentiation. Starting from a standardized pool of iPSCs, relative expression levels of two pluripotency genes, Oct4 and Zfp42, statistically correlated with enhanced cardiogenicity independent of somatic origin or reprogramming strategy (R2 = 0.85). These studies demonstrate that predictable iPSC differentiation is independent of somatic origin with standardized gene expression selection criteria, while the residual impact of reprogramming strategy greatly influences predictable output of tissue-specification required for comparative genotype/phenotype analyses. Stem Cells 2014;32:2350–2359
In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers
Felício, André C. , Dinelle, Katherine, Agarwal, Pankaj , McKenzie, Jessamyn , Heffernan, Nicole, Road, Jeremy , Appel‐Cresswell, Silke , Farrer, Matthew J. , Schulzer, Michael, Stoessl, A. Jon , Wszołek, Zbigniew K. , Sossi, Vesna , Appel-Cresswell, Silke

Mayo Clinic

Movement Disorders | May 5, 2014 | Volume: 29 | Issue: 9 | Pages: 1197-1201

10.1002/mds.25893 | PMID 24797316 Get It

ABSTRACTIntroductionWe used positron emission tomography (PET) to assess dopaminergic and serotonergic terminal density in three subjects carrying a mutation in the DCT1 gene, two clinically affected with Perry syndrome.MethodsAll subjects had brain imaging using 18F‐6‐fluoro‐l‐dopa (FDOPA, dopamine synthesis and storage), (+)‐11C‐dihydrotetrabenazine (DTBZ, vesicular monoamine transporter type 2), and 11C‐raclopride (RAC, dopamine D2/D3 receptors). One subject also underwent PET with 11C‐3‐amino‐4‐(2‐dimethylaminomethyl‐phenylsulfanyl)‐benzonitrile (DASB, serotonin transporter).ResultsFDOPA‐PET and DTBZ‐PET in the affected individuals showed a reduction of striatal tracer uptake. Also, RAC‐PET showed higher uptake in these area. DASB‐PET showed significant uptake changes in left orbitofrontal cortex, bilateral anterior insula, left dorsolateral prefrontal cortex, left orbitofrontal cortex, left posterior cingulate cortex, left caudate, and left ventral striatum.ConclusionsOur data showed evidence of both striatal dopaminergic and widespread cortical/subcortical serotonergic dysfunctions in individuals carrying a mutation in the DCTN1 gene. © 2014 International Parkinson and Movement Disorder Society
Pathogenesis and Treatment of Dupuytren Disease
Riester, Scott M. , Wijnen, André J. van , Rizzo, Marco , Riester, Scott, Kakar, Sanjeev , van Wijnen, Andre J

Mayo Clinic

JBJS Reviews | April 9, 2014 | Volume: 2 | Issue: 4 | Pages: No page available

10.2106/jbjs.rvw.m.00072 | PMID 27490872 Get It

Concise Review: Pluripotent Stem Cell-Based Regenerative Applications for Failing β-Cell Function
Holditch, Sara J., Ikeda, Yasuhiro , Terzic, André

Mayo Clinic

Stem Cells Translational Medicine | March 20, 2014 | Volume: 3 | Issue: 5 | Pages: 653-661

10.5966/sctm.2013-0184 | PMID 24646490 Get It

Abstract Diabetes engenders the loss of pancreatic β-cell mass and/or function, resulting in insulin deficiency relative to the metabolic needs of the body. Diabetic care has traditionally relied on pharmacotherapy, exemplified by insulin replacement to target peripheral actions of the hormone. With growing understanding of the pathogenesis of diabetic disease, alternative approaches aiming at repair and restoration of failing β-cell function are increasingly considered as complements to current diabetes therapy regimens. To this end, emphasis is placed on transplantation of exogenous pancreas/islets or artificial islets, enhanced proliferation and maturation of endogenous β cells, prevention of β-cell loss, or fortified renewal of β-like-cell populations from stem cell pools and non-β-cell sources. In light of emerging clinical experiences with human embryonic stem cells and approval of the first in-human trial with induced pluripotent stem cells, in this study we highlight advances in β-cell regeneration strategies with a focus on pluripotent stem cell platforms in the context of translational applications.
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
Wang, Michael , Popplewell, Leslie , Collins, Robert H. , Winter, Jane N. , Kaminski, Mark , Bartlett, Nancy L. , Johnston, Patrick B. , Lister, John , Fanning, Suzanne, Tuscano, Joseph M. , Robeva, Anna, Fan, Jenna, Klimovsky, Judith, Cheung, Wing, Cherfi, Azzeddine , O’Connor, Owen A. , Goy, Andre Henri , Beck, J. Thaddeus , Kaya, Hakan , Bartlett, Nancy L , Winter, Jane N

Mayo Clinic

British Journal of Haematology | March 3, 2014 | Volume: 165 | Issue: 4 | Pages: 510-518

10.1111/bjh.12780 | PMID 24579926 Get It